US FDA APPROVES BYDUREON® PEN (EXENATIDE EXTENDED-RELEASE FOR INJECTABLE SUSPENSION) FOR ONCE-WEEKLY TREATMENT OF ADULTS with TYPE 2 DIABETES AstraZeneca today announced that the US Food and Drug ...

In clinical trials, treatment with Bydureon BCise resulted in average HbA1c reductions of up to 1.4% and average weight loss of up to 3.1 pounds when used as monotherapy or as an add-on to metormin, a ...

First and Only Once-Weekly Type 2 Diabetes Medication Delivers Powerful Glycemic Control in a Single Dose INDIANAPOLIS, SAN DIEGO and WALTHAM, Mass., June 21, 2011 /PRNewswire/ -- Eli Lilly and ...

Below are 3 natural substitutes to Bydureon that can reduce body weight and control blood sugar levels. For best results it is possible to use in a stack – this means combining 2 or more products ...

The US Food and Drug Administration (FDA) has approved extended-release exenatide in a pen form for the treatment of adults with type 2 diabetes, according to the manufacturer. AstraZeneca's exenatide ...

SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass., Mar 03, 2011 (BUSINESS WIRE) -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today ...

BYDUREON BCISE The expanded approval was based on data from a phase 3 study that evaluated exenatide extended-release in 82 patients aged 10 to 17 years with type 2 diabetes. The Food and Drug ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the US Food and Drug Administration (FDA) has approved BYDUREON ® (exenatide extended-release) for injectable suspension as an add-on ...

Eli Lilly and Company together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ...

SAN DIEGO, June 24 (Reuters) - Analysis of an earlier trial found a "clinically insignificant" link between changes in heart rhythms and use of Bydureon, a long-acting diabetes drug being developed by ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon® Pen (exenatide extended-release for injectable ...

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced that the European Commission has granted marketing authorization to Bydureon (exenatide 2 mg powder and ...